Table 2.
Factors associated with negative SARS-CoV-2 antibodies in CLD patients with booster vaccination.
| Categories | Risk factors | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| NAbs against BA.4/5 | Age (years) | 1.096 | 1.031–1.166 | 0.003 | 1.014 | 1.004–1.024 | 0.006 |
| Male, n | 1.571 | 0.463–5.332 | 0.468 | / | |||
| Time after last vaccine (days) | 1.016 | 1.006–1.026 | 0.001 | 1.085 | 1.018–1.156 | 0.012 | |
| Total anti-SARS-CoV-2 antibodies | Age (years) | 1.056 | 0.985–1.132 | 0.124 | / | ||
| Male, n | 2.782 | 0.319–24.262 | 0.354 | / | |||
| White cell count ( × 109/L) | 0.497 | 0.251–0.982 | 0.044 | 0.631 | 0.354–1.122 | 0.117 | |
| HBcAb (S/CO) | 0.654 | 0.466–0.918 | 0.014 | 0.842 | 0.637–1113 | 0.227 | |
| Severe liver disease, n | 5.667 | 1.009–31.82 | 0.049 | 0.856 | 0.154–4.753 | 0.859 | |
NAb, neutralizing antibody; HBcAb, hepatitis B core antibody; OR, odds ratio.